Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the ...

The role of anesthetics in streamlining efficiency and elevating patient care.

assistant professor at Emory Eye CenterArticles ASRS 2025: Outcomes in patients with noninfectious uveitis requiring secondary lens implantation Sruthi Arepalli, MD; Martin David Harp; Sydney M Crago ...

Panelists discuss how they present the modest efficacy of geographic atrophy (GA) therapies to patients by framing treatment as maintenance therapy that slows progression rather than providing ...

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

Retina Group of WashingtonLai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

EP: 4. Choosing Between the Currently Available GA Therapies Therapy selection between the 2 FDA-approved geographic atrophy treatments presents a complex clinical decision without clear superiority ...

Avant Technologies and Ainnova Tech refine clinical trial protocol for Vision AI platform, aiming for FDA 510(k) approval to enhance diabetic retinopathy detection.